Generic Name:
Olaparib
Project Status:
Active
Therapeutic Area:
metastatic castration-resistant prostate cancer (mCRPC)
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Lynparza
Project Line:
Reimbursement Review
Project Number:
PC0223-000
NOC Date:
Details
Strength:
100 mg and 150 mg
Tumour Type:
Genitourinary
Indications:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Funding Request:
As monotherapy for the treatment of adult patients with mCRPC and deleterious or suspected deleterious germline and/or somatic mutations in the HRR genes BRCA or ATM who have progressed following prior treatment with a NHA.
Review Status:
Notification to Implement Issued
Sponsor:
AstraZeneca Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
pERC Meeting:
Final Recommendation Issued: